Burkholderia Infections - Pipeline Review, H2 2016

  • ID: 4030253
  • Report
  • 75 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Arno Therapeutics Inc
  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc
  • Eumedica SA
  • Grifols SA
  • Sarepta Therapeutics Inc
  • MORE
Burkholderia Infections - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia Infections - Pipeline Review, H2 2016, provides an overview of the Burkholderia Infections (Infectious Disease) pipeline landscape.

Burkholderia infections are caused by Burkholderia cepacia bacteria. Symptoms include low-grade fever, progressing to much more serious conditions, including pneumonia, cough, congestion, shortness of breath, and wheezing. Predisposing factors include weakened immune system and lung diseases. Treatment includes antibiotics.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Burkholderia Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Burkholderia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burkholderia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Burkholderia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Burkholderia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Burkholderia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Burkholderia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia Infections (Infectious Disease)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Burkholderia Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Burkholderia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Arno Therapeutics Inc
  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc
  • Eumedica SA
  • Grifols SA
  • Sarepta Therapeutics Inc
  • MORE
Introduction

Burkholderia Infections Overview

Therapeutics Development

Pipeline Products for Burkholderia Infections - Overview

Pipeline Products for Burkholderia Infections - Comparative Analysis

Burkholderia Infections - Therapeutics under Development by Companies

Burkholderia Infections - Therapeutics under Investigation by Universities/Institutes

Burkholderia Infections - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Burkholderia Infections - Products under Development by Companies

Burkholderia Infections - Products under Investigation by Universities/Institutes

Burkholderia Infections - Companies Involved in Therapeutics Development

Aridis Pharmaceuticals LLC

Arno Therapeutics Inc

Bavarian Nordic A/S

Emergent BioSolutions Inc

Eumedica SA

Grifols SA

Sarepta Therapeutics Inc

Soligenix Inc

Syntiron LLC

TGV-Laboratories

Vault Pharma Inc

Burkholderia Infections - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit Nucleoporin p62 for Burkholderia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-3100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-3150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia pseudomallei vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dusquetide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EV-035 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-072 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melioidosis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Panaecin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGX-943 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

temocillin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-231 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia Infections - Dormant Projects

Burkholderia Infections - Discontinued Products

Burkholderia Infections - Product Development Milestones

Featured News & Press Releases

May 31, 2016: FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis

Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC

Aug 14, 2014: US DTRA to fund preclinical work on Evolva’s antibiotic GC-072

Feb 21, 2014: Bavarian Nordic’s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development

Feb 21, 2014: Bavarian Nordic’s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development

Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis

Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Burkholderia Infections, H2 2016

Number of Products under Development for Burkholderia Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Burkholderia Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016

Burkholderia Infections - Pipeline by Arno Therapeutics Inc, H2 2016

Burkholderia Infections - Pipeline by Bavarian Nordic A/S, H2 2016

Burkholderia Infections - Pipeline by Emergent BioSolutions Inc, H2 2016

Burkholderia Infections - Pipeline by Eumedica SA, H2 2016

Burkholderia Infections - Pipeline by Grifols SA, H2 2016

Burkholderia Infections - Pipeline by Sarepta Therapeutics Inc, H2 2016

Burkholderia Infections - Pipeline by Soligenix Inc, H2 2016

Burkholderia Infections - Pipeline by Syntiron LLC, H2 2016

Burkholderia Infections - Pipeline by TGV-Laboratories, H2 2016

Burkholderia Infections - Pipeline by Vault Pharma Inc, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Burkholderia Infections - Dormant Projects, H2 2016

Burkholderia Infections - Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for Burkholderia Infections, H2 2016

Number of Products under Development for Burkholderia Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aridis Pharmaceuticals LLC
  • Arno Therapeutics Inc
  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc
  • Eumedica SA
  • Grifols SA
  • Sarepta Therapeutics Inc
  • Soligenix Inc
  • Syntiron LLC
  • TGV-Laboratories
  • Vault Pharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll